STOCK TITAN

Biohaven (NYSE: BHVN) shareholders back directors, auditors and pay plan

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Biohaven Ltd. reported the results of its 2026 annual meeting of shareholders. Shareholders elected Michael T. Heffernan, Irina Antonijevic, M.D., Ph.D., and Robert J. Hugin as directors for terms expiring at the 2029 annual meeting, each receiving over 76 million votes in favor and more than 14 million votes against, with additional abstentions and 32,137,064 broker non-votes.

Shareholders also approved the ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, with 123,723,636 votes for, 214,123 against, and 1,410,634 abstentions. In addition, they approved the non-binding advisory vote on compensation for the company’s named executive officers, with 87,521,620 votes for, 4,202,883 against, 1,486,826 abstentions, and 32,137,064 broker non-votes.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Votes for Heffernan 76,133,746 votes Election of director Michael T. Heffernan
Votes for Antonijevic 76,612,017 votes Election of director Irina Antonijevic, M.D., Ph.D.
Votes for Hugin 76,597,707 votes Election of director Robert J. Hugin
Auditor ratification for votes 123,723,636 votes Ratification of Ernst & Young LLP for 2026
Auditor ratification against votes 214,123 votes Opposed to Ernst & Young LLP ratification
Say-on-pay for votes 87,521,620 votes Advisory vote on executive compensation
Broker non-votes on Proposals 1 & 3 32,137,064 votes Director elections and say-on-pay
Annual Meeting financial
"held its 2026 annual meeting of shareholders (the “Annual Meeting”)."
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
Broker Non-Votes financial
"Broker Non-Votes: 32,137,064"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent auditors financial
"Ratification of the appointment of Ernst & Young LLP as independent auditors"
Independent auditors are outside, licensed accountants who examine a company’s books, records and internal controls and issue an objective opinion on whether the financial statements accurately reflect the business’s financial position. Investors treat their report like a neutral inspector’s stamp — it increases trust, makes financial results easier to compare, and alerts readers if there are errors, omissions or other problems that could affect investment decisions.
advisory vote financial
"Advisory vote on the compensation paid to the Company’s named executive officers."
An advisory vote is a shareholder poll that expresses investors’ approval or concern about a company’s policy, executive pay, board decisions or other governance matters but does not legally force the company to act. Think of it like a customer survey: it signals investor sentiment and can pressure management to change course, so investors watch the result as a guide to future governance, risk and potential shifts in strategy.
named executive officers financial
"compensation paid to the Company’s named executive officers."
Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
0001935979false00019359792026-04-282026-04-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 28, 2026
Biohaven Ltd.
(Exact name of registrant as specified in its charter)
British Virgin Islands001-41477Not applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
c/o Biohaven Pharmaceuticals, Inc.
215 Church Street
New Haven, Connecticut 06510
(Address of principal executive offices, including zip code)
(203) 404-0410
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common Shares, no par valueBHVNNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 




Item 5.07
Submission of Matters to a Vote of Security Holders.

On April 28, 2026, Biohaven Ltd. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”).

Set forth below are the results of the matters submitted for a vote of shareholders at the Annual Meeting.
Proposal No. 1: Election of directors for a term expiring at the 2029 Annual Meeting of Shareholders.

Votes ForVotes AgainstAbstained
Proposal No. 1(a): Michael T. Heffernan
76,133,746
15,092,665
1,984,918
Proposal No. 1(b): Irina Antonijevic, M.D., Ph.D.
76,612,017
14,616,115
1,983,197
Proposal No. 1(c): Robert J. Hugin
76,597,707
14,626,151
1,987,471
Broker Non-Votes: 32,137,064
All nominees were elected.
Proposal No. 2: Ratification of the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026.
Votes ForVotes AgainstAbstained
Ratification of appointment of Ernst & Young LLP
123,723,636
214,123
1,410,634
Broker Non-Votes: 0
Proposal No. 2 was approved.

Proposal No. 3: Advisory vote on the compensation paid to the Company’s named executive officers.
Votes ForVotes AgainstAbstained
Non-binding vote on the compensation of the Company’s named executive officers
87,521,620
4,202,883
1,486,826
Broker Non-Votes: 32,137,064
Proposal No. 3 was approved.

2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 4, 2026
Biohaven Ltd.
By:/s/ Matthew Buten
Matthew Buten
Chief Financial Officer


3

FAQ

What did Biohaven Ltd. (BHVN) shareholders decide at the 2026 annual meeting?

Shareholders elected three directors for terms expiring at the 2029 annual meeting, ratified Ernst & Young LLP as independent auditors for 2026, and approved a non-binding advisory vote on executive compensation, each proposal receiving more votes for than against.

Which directors were elected at Biohaven Ltd. (BHVN)’s 2026 annual meeting?

Shareholders elected Michael T. Heffernan, Irina Antonijevic, M.D., Ph.D., and Robert J. Hugin as directors. Their terms will expire at the 2029 annual meeting of shareholders, and each nominee received over 76 million votes in favor, with additional votes against and abstentions.

How did Biohaven Ltd. (BHVN) shareholders vote on the 2026 auditor ratification?

Shareholders approved the ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026. The vote totals were 123,723,636 for, 214,123 against, and 1,410,634 abstentions, with no broker non-votes reported for this proposal.

What were the results of Biohaven Ltd. (BHVN)’s say-on-pay advisory vote in 2026?

Shareholders approved the non-binding advisory vote on compensation for Biohaven’s named executive officers. The proposal received 87,521,620 votes for, 4,202,883 against, and 1,486,826 abstentions, with 32,137,064 broker non-votes recorded on this executive compensation item.

Were there broker non-votes at Biohaven Ltd. (BHVN)’s 2026 annual meeting?

Yes. For the director elections and the advisory vote on executive compensation, there were 32,137,064 broker non-votes. For the proposal to ratify Ernst & Young LLP as independent auditors for 2026, there were zero broker non-votes reported in the voting results.

Filing Exhibits & Attachments

3 documents